VHVerity Hartill

Verity Hartill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Verity Hartill has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Colin A. Johnson

    Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, UK

    4 shared publications
  • Kathryn E. Hentges

    Division of Evolution, Infection and Genomics, BHF Manchester Centre of Research Excellence, School of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester

    3 shared publications
  • Mitra Kabir

    Affiliation Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, British Heart Foundation Centre of Research Excellence, The University of Manchester, Manchester, United Kingdom

    3 shared publications
  • Wasay Mohiuddin Shaikh Qureshi

    Affiliation Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, British Heart Foundation Centre of Research Excellence, The University of Manchester, Manchester, United Kingdom

    3 shared publications
  • Andrew J. Doig

    University of Manchester

    2 shared publications
  • Bernard D. Keavney

    Affiliations Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester, United Kingdom Manchester Heart Institute, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, British Heart Foundation Centre of Research Excellence, Manchester, United Kingdom

    2 shared publications

Latest Publications

  • Open Access

    A machine learning classifier to identify and prioritise genes associated with murine cardiac development

    by Mitra Kabir, Verity Hartill, Gist H. Farr Iii, Wasay Mohiuddin Shaikh Qureshi, Stephanie L. Baross, Andrew J. Doig, David Talavera, Michael R. Waterfield, Bernard D. Keavney, Lisa Maves, et al.

    Congenital heart disease (CHD) is a major cause of infant mortality and presents life-long challenges to individuals living with these conditions. Genetic causes are known for only a minority of types of CHD. Discovering further genetic causes is limited by challenges in prioritising candidate genes. We examined a wide range of features of mouse genes, including sequence characteristics, protein localisation and interaction data, developmental expression data and gene ontology annotations. Many features differ between genes needed for cardiac development and non-cardiac genes, suggesting that these two gene types can be distinguished by their attributes. We therefore developed a supervised machine learning (ML) method to identify Mus musculus genes with a high probability of being involved in cardiac development. These genes, when mutated, are candidates for causing human CHD. Our classifier showed a cross-validation accuracy of 81% in detecting cardiac and non-cardiac genes. From our classifier we generated predictions of the cardiac development association status for all protein-coding genes in the mouse genome. We also cross-referenced our predictions with datasets of known human CHD genes, determining which are orthologues of predicted mouse cardiac genes. Our predicted cardiac genes have a high overlap with human CHD genes. Thus, our predictions could inform the prioritisation of genes when evaluating CHD patient sequence data for genetic diagnosis. Knowledge of cardiac developmental genes may speed up reaching a genetic diagnosis for patients born with CHD.

  • Open Access

    Molecular diagnoses and candidate gene identification in the congenital heart disease cohorts of the 100,000 genomes project

    by Verity Hartill, Mitra Kabir, Sunayna Best, Wasay Mohiuddin Shaikh Qureshi, Stephanie L. Baross, Jenny Lord, Jing Yu, Erina Sasaki, Hazel Needham, Deborah Shears, et al.

    Congenital heart disease (CHD) describes a structural cardiac defect present from birth. A cohort of participants recruited to the 100,000 Genomes Project (100 kGP) with syndromic CHD (286 probands) and familial CHD (262 probands) were identified. “Tiering” following genome sequencing data analysis prioritised variants in gene panels linked to participant phenotype. To improve diagnostic rates in the CHD cohorts, we implemented an agnostic de novo Gene Discovery Pipeline (GDP). We assessed de novo variants (DNV) for unsolved CHD participants following filtering to select variants of interest in OMIM-morbid genes, as well as novel candidate genes. The 100kGP CHD cohorts had low rates of pathogenic diagnoses reported (combined CHD “solved” 5.11% (n = 28/548)). Our GDP provided diagnostic uplift of nearly one third (1.28% uplift; 5.11% vs. 6.39%), with a new or potential diagnosis for 9 additional participants with CHD. When a filtered DNV occurred within a non-morbid gene, our GDP prioritised biologically-plausible candidate CHD genes (n = 79). Candidate variants occurred in both genes linked to cardiac development (e.g. AKAP13 and BCAR1) and those currently without a known role (e.g. TFAP2C and SETDB1). Sanger sequencing of a cohort of patients with CHD did not identify a second de novo variant in the candidate dataset. However, literature review identified rare variants in HMCN1, previously reported as causative for pulmonary atresia, confirming the approach utility. As well as diagnostic uplift for unsolved participants of the 100 kGP, our GDP created a dataset of candidate CHD genes, which forms an important resource for further evaluation.


  • Open Access

    A Machine Learning Classifier to Identify and Prioritise Genes Associated with Cardiac Development

    by Mitra Kabir, Verity Hartill, Gist H. Farr, Wasay Mohiuddin Shaikh Qureshi, Stephanie L. Baross, Andrew J. Doig, David Talavera, Bernard D. Keavney, Lisa Maves, Colin A. Johnson, et al.

    Congenital heart disease (CHD) is a major cause of infant mortality and presents life-long challenges to individuals living with these conditions. Genetic causes are known for only a minority of types of CHD. Discovering further genetic causes is limited by challenges in prioritising candidate CHD genes. We examined a wide range of features of mouse genes, including sequence characteristics, protein localisation and interaction data, developmental expression data and gene ontology annotations. Many features differ between cardiac development and non-cardiac genes, suggesting that these two gene types can be distinguished by their attributes. Therefore, we developed a supervised machine learning (ML) method to identify Mus musculus genes with a high probability of being involved in cardiac development. These genes, when mutated, are candidates for causing human CHD. Our classifier showed a cross-validation accuracy of 81% in detecting cardiac and non-cardiac genes. From our classifier we generated predictions of the cardiac development association status for all protein-coding genes in the mouse genome. We also cross-referenced our predictions with datasets of known human CHD genes, determining which are orthologues of predicted mouse cardiac genes. Our predicted cardiac genes have a high overlap with human CHD genes. Thus, our predictions could inform the prioritisation of genes when evaluating CHD patient sequence data for genetic diagnosis. Knowledge of cardiac developmental genes may speed up reaching a genetic diagnosis for patients born with CHD. Author Summary: Congenital heart disease arises during pregnancy when the heart has formed incorrectly. These malformations affect ∼1% of newborns. Yet, despite their frequency, the underlying causes are still not known in many cases. It is clear that genetic factors contribute to these defects, and increasingly DNA sequencing is used to attempt to determine if an individual has a genetic change causative of their condition. However, analysis of patient sequence data often reveals changes that are difficult to interpret due to a lack of knowledge of the function of the gene harbouring a sequence change. We aimed to facilitate the process of sequence evaluation by predicting which genes of unknown function are likely involved in heart formation. Our predictions agree with novel experimental evidence about genes needed for heart development. We found that when mutated, a high proportion of the predicted cardiac genes do indeed cause heart defects. This result suggests that our predictions may be informative for expanding our understanding of the genetic basis of congenital heart disease.


  • Open Access

    1373 Rapid exome sequencing for acutely unwell children: experiences from Yorkshire regional genetics service

    by Dimitra-Ilektra Lerou, Jasmine Meng Yin Chen, Melody Redman, Zena Lam, Verity Hartill, Jennifer Campbell

    Background Rare monogenic disorders in children and babies are difficult to diagnose, however establishing the diagnosis plays an important role in informing patient management and influencing clinical decision-making. On 1st October 2019, the National Rapid Exome Sequencing Service for acutely unwell children with a likely monogenic disorder (R14) was introduced across NHS England, via the National Genomic Test Directory. All Neonatal Intensive Care Units (NICUs) in England have access to the national R14 service. Informed consent for this test is essential, as the results may give uncertain or unexpected information, including about a child’s biological parents. Rapid trio Whole Exome Sequencing (WES) via R14 has enabled urgent diagnoses to be sought where this may affect the clinical management of the child. Objectives We undertook an audit and service evaluation of the R14 service in our region by reviewing all referrals to Yorkshire Regional Genetics Service (YRGS) over a one-year period since the commencement of the R14 service. Methods We reviewed all R14 referrals from YRGS to the nationally-commissioned Exeter Genomics Lab between 1st October 2019 and 30th September 2020. Our data collection tool enabled a standardised screening of patient notes, electronic patient records and genomic and other test results. Patient demographics, clinical and phenotypic information, and genomic outcome data were collected. Results 46 cases were identified; 18 male (39%), 28 female (61%). The median age of the proband at time of review was 20 days. A heat map demonstrated that most patients who had accessed the service were concentrated in West Yorkshire. At the time of request, 65% (n=30) of patients were on NICU. In 50% (n=23), the neonatal unit requested the test. In 43% (n=20), Clinical Genetics requested the test. In 4% (n=2), the test was requested by neurology, and 2% (n=1) by a High Dependency Unit. Request forms were fully complete in 74% (n=34) of cases. In 46% (n=21) of cases, consent for testing (via a record of discussion form) was not documented. The mean turnaround time from receipt of samples by the Exeter Genomics Lab to issuing of final reports was 12.7 days (range 7–25 days). In 52% (n=24) of cases, a genetic cause for the patient’s presentation was identified. Of these 24 cases, 96% (n=23) resulted in a change in management. The most common change in management was referral to a specialist (52%; n=12). Conclusions The R14 service for acutely unwell children heavily relies on effective collaboration between Neonatal and Clinical Genetics teams, as both teams are involved in the referral process. It is important that we improve our documentation – particularly around consent for testing - and ensure request forms are fully completed before submission. In over half of our cases, a genetic cause for the patient’s presentation was identified; in all but one of these cases, this affected some aspect of patient management. This audit has helped us to identify strategies to ensure equitable access to the R14 service across our region.

  • Open Access

    Investigation into the Importance of genes encoding ciliary proteins in congenital heart disease using whole exome sequencing

    by V Hartill, C Logan, DA Parry, K Szymanska, K Ashcroft, K English, K Prescott, A Dobbie, S Barwick, C Bennett, et al.

  • An unusual phenotype of X‐linked developmental delay and extreme behavioral difficulties associated with a mutation in the EBP gene

    by Verity L. Hartill, Carolyn Tysoe, Nigel Manning, Angus Dobbie, Saikat Santra, John Walter, Richard Caswell, Janet Koster, Hans Waterham, Emma Hobson

    We report on a family in which four males over three generations are affected with X‐linked recessive developmental delay, learning difficulties, severe behavioral difficulties and mild dysmorphic features. Plasma sterol analysis in three of the four affected males demonstrated increased concentrations of 8‐dehydrocholesterol (8‐DHC) and cholest‐8(9)‐enol. All four affected males had a novel hemizygous missense mutation, p.W47R (c.139T>C), in EBP. Functional studies showed raised levels of cholest‐8(9)‐enol in patient's cultured fibroblast cells, which were suppressed when the cells were incubated with simvastatin. EBP encodes 3β‐hydroxysteroid‐delta8, delta7‐isomerase, a key enzyme involved in the cholesterol biosynthesis pathway. Mutations in EBP have previously been associated with Conradi–Hunermann–Happle syndrome (CHH), an X‐linked dominant disorder characterized by skeletal dysplasia, skin, and ocular abnormalities, which is usually lethal in males. Four previous reports describe X‐linked recessive multiple anomaly syndromes associated with non‐mosaic EBP mutations in males, two at the same amino acid position, p.W47C. This phenotype has previously been described as “MEND” syndrome (male EBP disorder with neurological defects). The family reported herein represent either a novel phenotype, or an expansion of the MEND phenotype, characterized by extreme behavioral difficulties and a scarcity of structural anomalies. Simvastatin therapy is being evaluated in two males from this family.


  • Mowat–Wilson syndrome associated with craniosynostosis

    by Verity L. Hartill, Maria Pendlebury, Emma Hobson